Close

hemotune

Redaktion

Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.

Kooperation

Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Wyss Zurich Translational Center; ETH Zürich; hemotune AG

Projektdaten

  • Projekt-Nr: GRS-024/16 
  • Förderbeitrag: CHF 440'000 
  • Bewilligung: 02.11.2016 
  • Dauer: 04.2017 - 04.2019 
  • Handlungsfeld: Pilotprojekte, 1998 - 2018

Projektleitung

Abstract

Many clinical conditions such as intoxications, systemic infections or autoimmune diseases are caused by substances that are distributed in the blood circulation. The specific removal of these disease-causing factors from a patient’s blood would be in many cases the most direct way of cure. But current blood purification methods are not applicable to specifically and efficiently remove larger biomolecules such as bacterial toxins or antibodies directly from a patient’s blood.

After years of research at ETH Zurich and University Hospital Zurich, we want to develop and bring a breakthrough blood purification approach based on highly magnetic nanoparticles to the clinics. These tiny non-toxic nanomagnets are chemically equipped with specific binding agents against harmful disease-causing substances. The nanomagnets are administered to an extracorporeal blood circuit which is connected to the patient’s blood stream. There they selectively bind to the harmful compounds. Before the blood flows back to the patient, the magnets are removed along with the target substances by a highly efficient magnetic separator.

Based on our prototype for animal trials, the project focuses on the development of a functional prototype for human application. It will allow doctors and caregivers to perform the therapy in an easy and safe manner and bring us another step closer to implementation of this revolutionary approach into clinical practice.

Was ist das Besondere an diesem Projekt?

The disruptive potential of this project lies within the application of magnetic nanoparticles as a therapeutic procedure for blood purification. The approach opens up new possibilities in the field of selective blood purification and can overcome current limitations in terms of selectivity, efficiency and blood compatibility. Focusing on hardware development, the contribution of Gebert Rüf Stiftung will advance the therapy from the lab to the bedside and allows preparation of a first-in-man clinical trial.

Stand/Resultate

In the first phase the requirements for the device were captured and the industry standards as well as the learnings from the animal prototype were evaluated to identify the right direction for the prototype development. In the current, second phase a first full scale functional prototype of the hardware is developed and assembled for preclinical testing.

Publikationen

Herrmann, I. K.; Schlegel, A.; Graf, R.; Schumacher, C. M.; Senn, N.; Hasler, M.; Gschwind, S.; Hirt, A.-M.; Günther, D.; Clavien, P.-A.; Stark, W. J.; Beck-Schimmer, B. Nanomagnet-Based Removal of Lead and Digoxin from Living Rats. Nanoscale 2013, 5 (18), 8718–8723;
Herrmann, I. K.; Urner, M.; Graf, S.; Schumacher, C. M.; Roth-Z’graggen, B.; Hasler, M.; Stark, W. J.; Beck-Schimmer, B. Endotoxin Removal by Magnetic Separation-Based Blood Purification. Adv. Healthc. Mater. 2013, 2 (6), 829–835;
Schumacher, C. M.; Herrmann, I. K.; Bubenhofer, S. B.; Gschwind, S.; Hirt, A.-M.; Beck-Schimmer, B.; Günther, D.; Stark, W. J. Quantitative Recovery of Magnetic Nanoparticles from Flowing Blood: Trace Analysis and the Role of Magnetization. Adv. Funct. Mater. 2013, 23 (39), 4888–4896.

Medienecho

Am Projekt beteiligte Personen

Lukas Langenegger, project manager, Wyss Zurich Translational Center / ETH Zürich; CEO hemotune
Corinne Hofer, CTO hemotune
Dr. Carlos Mora, COO hemotune

Letzte Aktualisierung dieser Projektdarstellung  05.11.2018